These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 9713905)
1. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Kapitany T; Meszaros K; Lenzinger E; Schindler SD; Barnas C; Fuchs K; Sieghart W; Aschauer HN; Kasper S Schizophr Res; 1998 Jul; 32(2):101-6. PubMed ID: 9713905 [TBL] [Abstract][Full Text] [Related]
2. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients. Lohmann PL; Bagli M; Krauss H; Müller DJ; Schulze TG; Fangerau H; Ludwig M; Barkow K; Held T; Heun R; Maier W; Rietschel M; Rao ML Pharmacopsychiatry; 2003; 36(2):73-8. PubMed ID: 12734765 [TBL] [Abstract][Full Text] [Related]
3. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Ohmori O; Suzuki T; Kojima H; Shinkai T; Terao T; Mita T; Abe K Schizophr Res; 1998 Jul; 32(2):107-13. PubMed ID: 9713906 [TBL] [Abstract][Full Text] [Related]
4. Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients. Liou YJ; Wang YC; Bai YM; Lin CC; Yu SC; Liao DL; Lin MW; Chen JY; Lai IC Neuropsychobiology; 2004; 49(4):167-73. PubMed ID: 15118351 [TBL] [Abstract][Full Text] [Related]
5. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients. Fu Y; Fan CH; Deng HH; Hu SH; Lv DP; Li LH; Wang JJ; Lu XQ Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169 [TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients. Lam LC; Garcia-Barcelo MM; Ungvari GS; Tang WK; Lam VK; Kwong SL; Lau BS; Kwong PP; Waye MM; Chiu HF Pharmacopsychiatry; 2001 Nov; 34(6):238-41. PubMed ID: 11778144 [TBL] [Abstract][Full Text] [Related]
7. Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics. Nikoloff D; Shim JC; Fairchild M; Patten N; Fijal BA; Koch WH; MacPherson A; Flockhart D; Yoon YR; Yoon JS; Kim YH; Shin JG Pharmacogenomics J; 2002; 2(6):400-7. PubMed ID: 12629505 [TBL] [Abstract][Full Text] [Related]
8. Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6. Ellingrod VL; Schultz SK; Arndt S Pharmacotherapy; 2002 Nov; 22(11):1416-9. PubMed ID: 12432967 [TBL] [Abstract][Full Text] [Related]
9. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. Plesnicar BK; Zalar B; Breskvar K; Dolzan V J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753 [TBL] [Abstract][Full Text] [Related]
10. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype. Jaanson P; Marandi T; Kiivet RA; Vasar V; Vään S; Svensson JO; Dahl ML Psychopharmacology (Berl); 2002 Jun; 162(1):67-73. PubMed ID: 12107620 [TBL] [Abstract][Full Text] [Related]
11. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms. Tiwari AK; Deshpande SN; Rao AR; Bhatia T; Lerer B; Nimgaonkar VL; Thelma BK Schizophr Res; 2005 Jun; 75(1):21-6. PubMed ID: 15820320 [TBL] [Abstract][Full Text] [Related]
12. Association of tardive dyskinesia with variation in CYP2D6: Is there a role for active metabolites? Koola MM; Tsapakis EM; Wright P; Smith S; Kerwin Rip RW; Nugent KL; Aitchison KJ J Psychopharmacol; 2014 Jul; 28(7):665-70. PubMed ID: 24595968 [TBL] [Abstract][Full Text] [Related]
13. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Patsopoulos NA; Ntzani EE; Zintzaras E; Ioannidis JP Pharmacogenet Genomics; 2005 Mar; 15(3):151-8. PubMed ID: 15861039 [TBL] [Abstract][Full Text] [Related]
14. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Andreassen OA; MacEwan T; Gulbrandsen AK; McCreadie RG; Steen VM Psychopharmacology (Berl); 1997 May; 131(2):174-9. PubMed ID: 9201806 [TBL] [Abstract][Full Text] [Related]